Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Interventions
Epcoritamab
Cyclophosphamide
+4 more
Locations
331
United States
University of Arizona Cancer Center - North Campus /ID# 227463
Tucson, Arizona, United States
Yuma Regional Medical Center /ID# 261527
Yuma, Arizona, United States
University of Arkansas for Medical Sciences /ID# 225703
Little Rock, Arkansas, United States
CBCC Global Research, Inc. /ID# 262037
Bakersfield, California, United States
Alta Bates Summit Medical Center for Research /ID# 229427
Berkeley, California, United States
Orange Coast Memorial Medical Center /ID# 229632
Fountain Valley, California, United States
Start Date
February 8, 2023
Primary Completion Date
June 1, 2027
Completion Date
December 1, 2029
Last Updated
January 23, 2025
NCT05272384
NCT06395103
NCT05139017
NCT01804686
NCT07443514
NCT05755087
Lead Sponsor
Genmab
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions